ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection

• Published in: Clinical lung cancer 2018-07, Vol.19 (4), p.e533-e536
• Main Authors: Wu, Yi-Long, Herbst, Roy S., Mann, Helen, Rukazenkov, Yuri, Marotti, Marcelo, Tsuboi, Masahiro
• Format: Article
• Language: English
• Subjects: Acrylamides; Adjuvant therapy; Aniline Compounds; Antineoplastic Agents - therapeutic use; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - surgery; Chemotherapy, Adjuvant - methods; Double-Blind Method; EGFR-TKI; ErbB Receptors - antagonists & inhibitors; ErbB Receptors - genetics; Humans; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Lung Neoplasms - surgery; Mutation; Non–small-cell lung cancer; Piperazines - therapeutic use; Research Design; Surgery; Tyrosine kinase inhibitor
• ISSN: 1525-7304; 1938-0690
• DOI: 10.1016/j.cllc.2018.04.004

Currently, the role of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as adjuvant therapy for early-stage non–small-cell lung cancer after complete surgical tumor resection remains under investigation. We present the rationale and study design for the ADAURA (ClinicalTrials.gov identifier, NCT02511106) trial, a multicenter, double-blind, randomized, placebo-controlled study. Study entry will be limited to adults aged ≥ 18 years (and in Japan and Taiwan, age ≥ 20 years) with primary nonsquamous stage IB-IIIA non–small-cell lung cancer with central confirmation of an EGFR exon 19 deletion or L858R mutation. Patients will be randomized 1:1 to receive osimertinib 80 mg once daily or placebo once daily until disease recurrence, a treatment discontinuation criterion is met, or patients achieve the maximum treatment duration of 3 years. The primary endpoint of this study is disease-free survival. Secondary endpoints include the disease-free survival rate at 2, 3, and 5 years, overall survival, overall survival rate at 5 years, and safety and tolerability. Health-related quality of life and pharmacokinetics will also be evaluated. The exploratory objectives include assessment of osimertinib efficacy in patients with a confirmed baseline T790M mutation status and postrecurrence outcomes, health resource use, and a comparison of plasma-derived circulating tumor DNA EGFR mutation status at baseline and at disease recurrence. Study enrollment began in August 2015, and results are expected in the third quarter of 2021 (depending on the actual event rate).